tardivedyskinesia
Conditions
Interventions
Consolation group:Give a placebo
12mg group:Administer 12mg of deuterated butylbenazine
24mg group:Administer 24mg of deuterated butylbenazine
36mg group:Administer 36mg of deuterated butylbenazine
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Consistent with the diagnosis of schizophrenia in ICD-11; 2. Continuous use of antipsychotic drugs for at least 3 months; 3. Over 18 years old; 4. After assessment by a clinical doctor, it is believed that the patient's condition and symptoms are stable; 5. Obtain the informed consent of the patient or their family and voluntarily sign the informed consent form to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Suffering from any other movement disorders (such as abnormal movements of the mouth and face caused by oral diseases like Parkinson's syndrome, Tourette syndrome, Huntington's disease, tooth loss, etc.); 2. Those with serious diseases of other systems; 3. Other circumstances that the researcher or clinician deems unsuitable for inclusion (such as pregnant or lactating women, having a history of alcohol/drug/psychoactive substance abuse or dependence, having suicidal tendencies, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Symptom Score Sheet (PANSS);Involuntary Movement Scale (AIMS); | — |
Secondary
| Measure | Time frame |
|---|---|
| General demographic data; | — |
Countries
China
Contacts
Public ContactMaosheng Ran
West China Hospital of Sichuan University
Outcome results
None listed